[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bph-benign-prostatic-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bph-benign-prostatic-hyperplasia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,38,68,97,124,150,174,203,232,257,279,307,329],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100638586","predicting-bph-surgery-outcomes-using-a-preoperative-scoring-system-100638586",false,"NCT07623239","Predicting BPH Surgery Outcomes Using a Preoperative Scoring System","Development and Clinical Application Value of a Predictive Scoring System for Postoperative Outcomes Following Transurethral Resection of the Prostate Based on Preoperative Multidimensional Objective Indicators","Inclusion Criteria:\n\n* \\- Postoperative pathological diagnosis of benign prostatic hyperplasia (BPH)\n* Completion of pelvic or prostate magnetic resonance imaging (MRI) plain scan within 1 month before surgery\n* Completion of urodynamic study within 1 month before surgery\n* Completion of International Prostate Symptom Score (IPSS) both before and after surgery\n* Complete and retrievable clinical and pathological data\n* Generally good condition without infection, autoimmune disease, hematologic disease, or other malignancies\n* Complete follow-up data with follow-up duration of at least 6 months after surgery\n\nExclusion Criteria:\n\n* \\- Concomitant prostate cancer or other malignancies\n* Prior prostate surgery or pelvic radiotherapy\n* Severe cardiac, pulmonary, hepatic, or renal insufficiency precluding tolerance of surgery\n* Intraoperative or postoperative severe complications affecting efficacy assessment\n* Follow-up duration less than 6 months or missing key data\n* Poor patient compliance precluding completion of necessary assessments and follow-up\n* Incomplete clinical, imaging, urodynamic, or pathological data, or loss to follow-up","MALE","30 Years","100 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","This study aims to develop and validate a preoperative predictive scoring system for surgical outcomes in patients with benign prostatic hyperplasia (BPH) undergoing prostate surgery (including but not limited to transurethral resection of the prostate, laser enucleation, photoselective vaporization, or robot-assisted simple prostatectomy).\n\nIt is a multicenter retrospective study involving patients from four hospitals in China. Preoperative multidimensional objective indicators, including clinical data, prostate MRI parameters, and urodynamic measurements, will be collected. The primary outcome is a favorable surgical response defined by a postoperative-to-preoperative International Prostate Symptom Score (IPSS) ratio ≤ 0.5 at 6 months after surgery.\n\nMultivariable logistic regression, restricted cubic splines, and bootstrap internal validation will be used to construct and evaluate the scoring system. The goal is to provide an objective, individualized tool for optimizing surgical decision-making in BPH patients.",[25],"BPH (Benign Prostatic Hyperplasia)","NOT_YET_RECRUITING","2026-05-29",{"date":29,"type":30},"2026-06-03","ACTUAL",{"date":32,"type":21},"2026-06-01",{"date":34,"type":21},"2027-09-01",{"name":36,"class":37},"First Affiliated Hospital of Fujian Medical University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100637322","a-single-center-single-arm-study-to-evaluate-the-safety-and-efficacy-of-ultra-minimally-invasive-prostate-dilation-in-treating-patients-with-significant-obstructive-symptoms-caused-by-benign-prostatic-hyperplasia-100637322","NCT07583706","A Single-center, Single-arm Study to Evaluate the Safety and Efficacy of Ultra-minimally Invasive Prostate Dilation in Treating Patients With Significant Obstructive Symptoms Caused by Benign Prostatic Hyperplasia","UMPD-BPH","Inclusion Criteria:\n\n* Male subjects aged 40 to 80 years with symptomatic benign prostatic hyperplasia (BPH) and obvious bladder outlet obstruction.\n* Subjects with normal sexual life and a sexual partner, and with intact sexual function.\n* International Prostate Symptom Score (IPSS) ≥ 13.\n* Maximum urinary flow rate (Qmax) between 5 and 10 mL\u002Fs, with a minimum voided volume ≥ 150 mL.\n* Prostate volume measured by transrectal ultrasound (TRUS) \\\u003C 30 mL. Prostate volume is calculated as length × width × height × 0.52.\n* Subjects who, in the investigator's opinion, are able to complete the study protocol.\n\nExclusion Criteria:\n\n* Subjects who are unable or unwilling to sign the informed consent form (ICF) and\u002For comply with all follow-up requirements.\n* Subjects who are unwilling to abstain from sexual activity or use protective sexual behavior within 90 days after treatment.\n* Prostate-specific antigen (PSA) ≥ 10 ng\u002FmL, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Use of antiplatelet drugs, such as clopidogrel or aspirin, within 10 days before surgery, or planned use within 5 days after surgery.\n* Use of medications within 3 months before surgery that, in the investigator's opinion, may affect sexual function.\n* Presence of neurogenic bladder or detrusor underactivity affecting bladder\u002Fsphincter function.\n* Patients with BPH complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.","40 Years","80 Years",{"count":48,"type":21},5,"INTERVENTIONAL",[51],"NA","This single-center, single-arm, prospective clinical study aims to preliminarily evaluate the safety and effectiveness of ultra-minimally invasive prostatic dilation using a prostate dilation catheter under real-time transrectal ultrasound (TRUS) guidance in male patients with significant bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH).\n\nA total of 5 eligible male subjects aged 40 to 80 years with symptomatic BPH, International Prostate Symptom Score (IPSS) ≥13, maximum urinary flow rate (Qmax) of 5-10 mL\u002Fs, prostate volume \\\u003C30 mL measured by TRUS, and evident bladder outlet obstruction will be enrolled. All subjects will undergo prostatic balloon dilation with the study device under real-time TRUS guidance. Follow-up assessments will be conducted at 1, 3, and 6 months after treatment.\n\nThe primary effectiveness endpoint is the change in IPSS from baseline at 1, 3, and 6 months. The primary safety endpoints include bladder neck contracture, retrograde ejaculation, device-related severe urinary retention persisting for more than 14 days after healing, new-onset stress urinary incontinence, device-related bleeding requiring transfusion, and device-related urethral or prostatic capsular rupture requiring surgical intervention.\n\nSecondary endpoints include responder rates based on different thresholds of IPSS improvement (≥30%, ≥40%, and ≥50%), changes in Qmax, and changes in visual analogue scale (VAS) scores. Exploratory endpoints include changes in postvoid residual urine volume (PVR) and sexual function assessed by the International Index of Erectile Function (IIEF-5) and the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD).\n\nThis exploratory study is intended to provide preliminary clinical evidence supporting the safety and potential clinical benefit of TRUS-guided ultra-minimally invasive prostatic dilation for BPH-related obstruction and to inform future larger-scale clinical studies.",[25],[55,56],"Benign Prostatic Hyperplasia","LUTS","RECRUITING","2026-05-07",{"date":60,"type":30},"2026-05-13",{"date":62,"type":30},"2026-01-01",{"date":64,"type":21},"2026-09-01",{"name":66,"class":37},"Qing Yuan",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":49,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":67},"100636459","holep-thulep---comparing-lasers-for-bph-surgery-100636459","NCT07565961","HoLEP-ThuLEP - Comparing Lasers for BPH Surgery","Prospective Randomized Comparative Study Evaluating Functional and Perioperative Outcomes After Thulium Laser Enucleation of the Prostate (ThuLEP) Versus Holmium Laser Enucleation of the Prostate (HoLEP)","HOT","Inclusion Criteria:\n\n* Male, age ≥ 18 years\n* Clinically relevant benign prostatic syndrome (BPS) with an established indication for surgical treatment\n* International Prostate Symptom Score (IPSS) ≥ 8\n* Prostate volume \\> 40 ml\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Proven or suspected prostate cancer\n* Previous surgery of the prostate or urethra\n* Neurogenic bladder dysfunction\n* Anticoagulation therapy that cannot be paused perioperatively","18 Years",{"count":78,"type":21},150,[51],"Benign prostatic hyperplasia (BPH) is a very common condition in older men. As the prostate enlarges, it can press on the urethra and make urination difficult. Typical symptoms include a weak urinary stream, frequent urination, getting up at night to urinate, and a feeling that the bladder is not fully empty. When medication is no longer sufficient, surgical removal of the inner part of the prostate (\"enucleation\") is the recommended treatment.\n\nTwo modern laser techniques are used for this operation. Holmium Laser Enucleation of the Prostate (HoLEP) is currently considered the reference standard, with very good long-term results and a low rate of re-operations. Thulium Laser Enucleation of the Prostate (ThuLEP) using a pulsed thulium laser is a newer alternative. Because the laser energy is delivered in short pulses, ThuLEP may allow more precise tissue cutting and better control of bleeding during surgery.\n\nSo far, only limited high-quality randomized data directly compare the two techniques, particularly for patient-reported outcomes such as urinary symptoms, continence, and erectile function.\n\nPurpose of the study The HoT-Trial investigates whether ThuLEP is as effective as HoLEP for men who need surgery for an enlarged prostate, and whether there are differences in recovery, complication rates, urinary symptoms, continence, and erectile function after surgery.\n\nResearch question Does ThuLEP lead to a similar improvement in lower urinary tract symptoms (LUTS) as HoLEP 12 months after surgery, measured by the change in the International Prostate Symptom Score (IPSS)?\n\nHow the study works A total of 150 men aged 18 years or older with clinically relevant BPH, an IPSS of 8 or higher, a prostate volume above 40 ml, and an indication for surgery will take part. Each participant will be randomly assigned (1:1) to either ThuLEP or HoLEP. Participants are blinded to the assigned technique (single-blind design). Both procedures are established, guideline-recommended treatments; taking part in the study does not add any risks beyond standard care.\n\nBefore surgery, participants complete standardized questionnaires (IPSS, ICIQ-SF, IIEF) and undergo uroflowmetry and residual urine measurement. Surgery is performed according to randomization. Participants are then followed up in the urology outpatient clinic at discharge and at 3, 6, and 12 months after surgery. The same measurements and questionnaires are repeated at each visit.\n\nPrimary outcome Change in IPSS from baseline to 12 months after surgery.\n\nSecondary outcomes Maximum urinary flow rate (Qmax) and post-void residual urine; continence (ICIQ-SF) and erectile function (IIEF); operative time, laser time, blood loss, transfusion rate; catheter indwelling time and length of hospital stay; peri- and postoperative complications graded by the Clavien-Dindo classification; and the rate of re-intervention or re-catheterization within 12 months.\n\nSetting and timeline The study is conducted as a single-center trial at the Department of Urology, Ludwig-Maximilians-University Munich, Germany. Recruitment runs for approximately two years, with up to 12 months of follow-up per participant. The total study period is planned from April 2026 to April 2029.\n\nBy directly comparing the two laser enucleation techniques in a randomized setting, the HoT-Trial aims to help patients and physicians choose the most suitable surgical treatment for benign prostatic hyperplasia.",[25],[83,84,85,86,87,88,89],"BPH","BPS","Enculeation","Prostate","Laser","HOLEP","THULEP","2026-05-02",{"date":58,"type":30},{"date":32,"type":21},{"date":94,"type":21},"2027-12-31",{"name":96,"class":37},"Ludwig-Maximilians - University of Munich",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100634356","prospective-post-market-clinical-registry-for-the-zenflow-spring-system---a-minimally-invasive-treatment-for-luts-associated-with-bph-spring-system-registry-100634356","NCT07538622","Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry","Inclusion Criteria:\n\n* Treatment with Zenflow Spring System will be conducted in accordance with the approved Instructions for Use\n\nExclusion Criteria:\n\n* Treatment with Zenflow Spring System will be conducted in accordance with the approved Instructions for Use",{"count":104,"type":21},300,"12 Months","The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up visits at 1, 3, 6, and 12 months. We will look at how symptoms improve, how quickly patients return to normal activities, how satisfied they are with treatment, and whether there are any problems or side effects related to the device.",[25],[109,110,83,55,111,112,56],"Benign Prostatic Hyperplasia (BPH)","Symptomatic BPH","enlarged prostate","lower urinary tract symptoms (LUTS)","2026-04-13",{"date":115,"type":30},"2026-04-20",{"date":117,"type":21},"2026-06",{"date":119,"type":21},"2028-09",{"name":121,"class":122},"Zenflow, Inc.","INDUSTRY",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":49,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":67},"100588649","phase-2-new-treatment-strategies-and-epigenetic-biomarker-for-management-of-benign-prostatic-hyperplasia-100588649","NCT06944145","New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia","A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)","Inclusion criteria\n\n1. ≥18 yrs old on the day of study consent;\n2. Finasteride has been recommended for treatment of BPH by a physician;\n3. PSA \\\u003C20ng\u002Fml within the last six months;\n4. Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics);\n5. Patient is able and willing to provide written informed consent.\n\nExclusion criteria\n\n1. Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis;\n2. Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci);\n3. History of pelvic radiation;\n4. Actively receiving intravesical therapy for bladder cancer;\n5. Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine);\n6. Current use of warfarin;\n7. Prior treatment with 5ARI medications (e.g., Finasteride or Dutasteride) in the last year;\n8. Diagnosed with diabetes mellitus;\n9. Diagnosed with any neurodegenerative diseases;\n10. History of allergic reaction to any intravenous (IV) iron replacement products;\n11. Currently taking cholestyramine medication;\n12. Contraindications to MRI examination, which may include:\n\n    * Cardiac pacemaker\n    * Intracranial clips, metal implants, or external clips within 10mm of the head\n    * Previous metal injury in the eye or occupation risk to ferrous metal in the eye (e.g. metalworker)\n    * Claustrophobia that cannot be managed with benzodiazepine",{"count":132,"type":21},242,[134],"PHASE2","SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.",[25,137],"Lower Urinary Track Symptoms",[83,139,140,56],"SRD5A2","Finasteride","2026-03-19",{"date":143,"type":30},"2026-03-23",{"date":145,"type":30},"2025-12-03",{"date":147,"type":21},"2030-08-31",{"name":149,"class":37},"Beth Israel Deaconess Medical Center",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":49,"phases":159,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100628775","phase-1-tadalafil-5-mg-on-storage-lower-urinary-tract-symptoms-after-anatomical-endoscopic-enucleation-of-the-prostate-100628775","NCT07466030","Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","Impact of Daily Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate :A Randomized , Single Blinded ,Controlled Trial\"","Inclusion Criteria:\n\n* Must be able to swallow tablets\n* Adult males undergoing elective AEEP for symptomatic benign prostatic hyperplasia (BPH) with prostate volume ≥40 ml , Moderate to severe LUTS defined by International Prostate Symptom Score (IPSS) ≥19 at baseline.\n* Patient is Willing to participate and able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to tadalafil (e.g., nitrate use, severe hepatic\u002Frenal impairment, uncontrolled hypotension) , neurogenic bladder. , Preoperative urinary catheter dependence , post-void residual urine \\>350 ml. ,, Cognitive impairment precluding questionnaire completion",{"count":158,"type":21},40,[160],"PHASE1","The aim of this study is to evaluate the impact of daily tadalafil 5 mg on storage lower urinary tract symptoms (LUTS) during the early postoperative period following Anatomical endoscopic enucleation of prostate in a randomized controlled clinical trial.",[25],[164],"Storage LUTS post AEEP","2026-03-07",{"date":167,"type":30},"2026-03-12",{"date":169,"type":21},"2026-03-01",{"date":171,"type":21},"2028-09-01",{"name":173,"class":37},"Assiut University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":49,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":67},"100622246","intupro-in-the-treatment-of-benign-prostatic-hyperplasia-related-symptoms-100622246","NCT07381127","INTUPRO in the Treatment of Benign Prostatic Hyperplasia-Related Symptoms","A Study to Evaluate the Safety and Efficacy of Ionic Fluid in Treating Symptoms in Patients With Benign Prostatic Hyperplasia. A Prospective, Single-arm, Single-center Clinical Study.","Inclusion Criteria:\n\n* • Male patient aged 45 years or older\n\n  * Prostate volume greater than 30 grams\n  * An International Prostate Symptom Score (IPSS) of 12 or higher\n  * Presence of obstructive urinary symptoms, such as difficulty starting urination, leakage of urine after voiding, or a feeling of incomplete bladder emptying.\n\nThis criterion may include patients who have previously been diagnosed with prostate cancer and completed treatment, but are experiencing urinary problems.\n\n* Life expectancy of at least 3 months\n* Ability to understand the study information and provide written informed consent\n* Willingness and ability to comply with all study requirements, including procedures, clinical assessments, and follow-up visits\n\nExclusion Criteria:\n\n* Urethral stricture\n\n  * Bladder stones\n  * Prostate volume 120 grams or greater\n  * Presence of a prostate median lobe\n  * History of bladder cancer or kidney cancer, and\u002For prior surgery related to these conditions\n  * Previous radiation therapy to the pelvic region\n  * Prior invasive surgical treatment for BPH symptoms\n  * The Principal Investigator believes the patient would not tolerate the procedure\n  * Presence of a cognitive impairment that, in the opinion of the Principal Investigator, would interfere with the patient's ability to provide reliable data or to safely complete the study\n  * Bleeding disorders\n  * Known allergy or intolerance to MRI contrast agents required for imaging used to evaluate treatment effectiveness after ionic fluid application\n  * Other significant concurrent medical conditions that, in the investigator's judgment, could prevent clinical benefit from the procedure or could place the patient or study objectives at risk (including, but not limited to, active infection, kidney dysfunction, or significant comorbidities)\n  * Significant medical or psychiatric illness\n  * Participation in another clinical study involving a device, drug, or procedure that has not been completed or that could affect the outcomes of this study\n  * Inability or unwillingness to undergo MRI examinations during the study period for any reason","45 Years",{"count":183,"type":21},31,[51],"The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).\n\nThe main questions it aims to answer are:\n\nCan INTUPRO treatment lead to the removal of the Foley catheter? Can INTUPRO treatment improve urinary flow? Can INTUPRO treatment lower or minimize waking during sleep to urinate? Can INTUPRO reduce urinary hesitancy, urgency and frequency?\n\nParticipants will:\n\nReceive INTUPRO treatment on Day 1. Visit at Day 30 and Day 90 for checkups, tests and Prostate MRI.",[25,83,187],"BPH With Other Lower Urinary Tract Symptoms",[189,190,191,192,193],"procedure","needle","benign prostate hyperplasia","moderate sedation","outpatient","2026-01-23",{"date":196,"type":30},"2026-02-02",{"date":198,"type":30},"2025-03-04",{"date":200,"type":21},"2027-12",{"name":202,"class":122},"inTumo Therapeutics, Inc.",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":46,"enrollmentInfo":212,"targetDuration":4,"studyType":49,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":67},"100619852","comparison-of-holmium-thuliumyag-and-thulium-fiber-lasers-in-prostate-enucleation-100619852","NCT07350005","Comparison of Holmium, Thulium:YAG, and Thulium Fiber Lasers in Prostate Enucleation","A Prospective Randomized Study Comparing the Efficiency and Safety of Holmium:YAG, Thulium:YAG, and Thulium Fiber Lasers in Anatomical Prostate Enucleation","TRI-LASER","Inclusion Criteria:\n\n* Patients diagnosed with benign prostatic hyperplasia (BPH) and scheduled for anatomical prostate enucleation\n* Presence of a prostate and clinical indication for surgical treatment\n* Age between 50 and 80 years\n\nExclusion Criteria:\n\n* History or suspicion of prostate cancer\n* Previous prostate surgery\n* Presence of neurogenic bladder or significant lower urinary tract dysfunction unrelated to BPH\n* Active urinary tract infection at the time of surgery\n* Severe comorbid conditions contraindicating surgery or anesthesia","50 Years",{"count":213,"type":21},159,[51],"Benign prostatic hyperplasia (BPH) is a common condition in aging men and may require surgical treatment when medical therapy is ineffective. Anatomical prostate enucleation using different laser technologies is a well-established surgical approach for the treatment of BPH.\n\nThe purpose of this prospective randomized study is to compare the efficiency and safety of three commonly used laser systems-Holmium:YAG, Thulium:YAG, and Thulium Fiber Laser (TFL)-during anatomical prostate enucleation.\n\nThe primary objective of the study is to evaluate laser efficiency by measuring grams of enucleated prostate tissue per joule (g\u002FJ) using intraoperative laser device data. Secondary outcomes include changes in International Prostate Symptom Score (IPSS) and the occurrence of postoperative urinary incontinence.\n\nAll laser systems used in this study are part of routine clinical practice, and no additional diagnostic procedures or treatments will be performed for study purposes",[25],[218,219,220,221,222],"bph","prostate","holmium","thulium","TFL","2026-01-14",{"date":225,"type":30},"2026-01-20",{"date":227,"type":21},"2026-05",{"date":229,"type":21},"2028-01",{"name":231,"class":37},"Ankara University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":49,"phases":241,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100608626","phase-4-comparison-of-convective-water-vapor-ablation-convective-water-vapor-energy-wave-with-the-rezum-system-versus-holmium-laser-enucleation-of-the-prostate-holep-versus-bipolar-transurethral-resection-of-the-prostate-tur-p-in-patients-with-benign-prostatic-syndrome-bps---a-randomized-study-100608626","NCT07204002","Comparison of Convective Water Vapor Ablation (Convective Water Vapor Energy, WAVE™) With the Rezum™ System Versus Holmium Laser Enucleation of the Prostate (HoLEP) Versus Bipolar Transurethral Resection of the Prostate (TUR-P) in Patients With Benign Prostatic Syndrome (BPS) - A Randomized Study","Vektor","Inclusion Criteria:\n\n* Age \\> 18 years\n* Patients with confirmed benign prostatic syndrome for whom surgical therapy is indicated\n* Prostate volume between 30 and 80 ml\n\nExclusion Criteria:\n\nLack of capacity to give informed consent\n\n* Emergency surgeries\n* Known prostate carcinoma\n* Elevated post-void residual urine \\> 300 ml\n* Neurogenic bladder emptying disorder\n* Urethral pathologies\n* High-intensity anticoagulation\n* Dual antiplatelet therapy\n* History of pelvic radiation\n* Chronic pelvic pain syndrome",{"count":240,"type":21},198,[242],"PHASE4","Benign prostatic enlargement (BPH\u002FBPS) is one of the most common benign diseases in adult men. About 50% of men are affected by the age of 50, and between the ages of 70 and 80 the prevalence rises to 70-80%.\n\nThere are various surgical procedures available for the treatment of BPH. In this study, we are investigating three surgical procedures which, based on the current data, appear to be relatively equivalent; however, additional data are still needed to substantiate this.\n\nThe aim of this study is to compare the three surgical methods REZUM vs. HoLEP vs. TUR-P for endoscopic transurethral subvesical de-obstruction with regard to both subjective and objective voiding function, as well as improvements in quality of life and sexual function.\n\nThe goal of the study is to work out the possible advantages and disadvantages for future patient counseling, thereby defining more precisely the role of these surgical procedures within the armamentarium of urology. This is a single-center, randomized, prospective interventional study.",[25,245,246,247],"HoLEP","Rezum","TURP(Transurethral Resection of Prostate)","2025-11-18",{"date":250,"type":30},"2025-11-19",{"date":252,"type":21},"2025-11-15",{"date":254,"type":21},"2030-10-15",{"name":256,"class":37},"Medical University of Graz",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":181,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":49,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100588991","impact-of-kegel-exercise-on-patient-outcomes-post-turp-100588991","NCT06948604","Impact of Kegel Exercise on Patient Outcomes Post TURP","Impact of Kegel Exercises on the Postoperative Outcomes of Patients Undergoing Transurethral Resection of the Prostate","Inclusion Criteria:\n\n* patient diagnosed with BPH and undergoing TURP\n* Patient age range from 45-65years old\n* Patient understand verbal and written instructions\n\nExclusion Criteria:\n\nPatient confirmed diagnosis with prostate cancer (biopsy-PSA) Conversion to open prostatectomy Patient has cognitive impairment Patient has chronic cough \u002Fchronic bronchitis or asthma","65 Years",{"count":266,"type":21},92,[51],"how kegel exercise will improve patient outcomes by reducing post TURP LUTs , improve patient performance status and improve patient self esteem",[25],[271],"Kegel exercise,TURP, Patient outcomes and BPH","2025-07-29",{"date":274,"type":30},"2025-08-01",{"date":274,"type":21},{"date":277,"type":21},"2026-11-01",{"name":173,"class":37},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":49,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":67},"100597991","phase-1-effetivity-of-dutasteride-and-aloe-vera-extract-combination-on-angiogenesis-and-obstruction-on-benign-prostatic-hyperplasia-100597991","NCT07065682","Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia","ALOE-DUTA-BPH","Inclusion Criteria:\n\n* Diagnosed with BPH clinically or radiologically (prostate volume \\> 30 gram, Qmax \\\u003C15 mL\u002Fs)\n* Willing to participate to the study\n\nExclusion Criteria:\n\n* Clinically or radiologically suspected of having prostatic cancer\n* Previous prostatic surgery\n* Patients with urinary retention\n* Patients with BPH complications: urinary tract infections, urolithiasis, or hydroneprhosis\n* Previously consumed alpha blocker or 5ARI in the last 6 months\n* Have consumed aloe vera extract routinely",{"count":287,"type":21},84,[160],"This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks",[25],[292,293,294,86,295,296,297],"Aloe Vera","Benign prostate hyperplasia","VEGF","dutasteride","uroflowmetry","prostatic hyperplasia","2025-07-03",{"date":300,"type":30},"2025-07-15",{"date":302,"type":30},"2023-07-01",{"date":304,"type":21},"2027-12-01",{"name":306,"class":37},"Universitas Diponegoro",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":67},"100594508","feasibility-and-safety-of-a-single-working-element-for-bipolar-and-laser-enucleation-in-prostate-surgery-a-prospective-study-100594508","NCT07020364","Feasibility and Safety of a Single Working Element for Bipolar and Laser Enucleation in Prostate Surgery: A Prospective Study","Inclusion Criteria:\n\n* Diagnosed with benign prostatic hyperplasia (BPH) requiring surgical intervention.\n* Prostate volume ≥40 cc (as assessed by transrectal ultrasound).\n* No prior history of prostate cancer.\n\nExclusion Criteria:\n\n* Patients with ongoing urinary tract infections.\n* Prior prostate surgeries.\n* Coagulation disorders or patients on long-term anticoagulation therapy.\n* Known urethral strictures or other anatomical abnormalities complicating endoscopic procedures.",{"count":314,"type":21},60,"A prospective feasibility study would be a practical first step, focusing on real-time assessment and ensuring the new working element's integration is safe and effective before broader clinical trials.",[86,25],[318,319,83,219],"laser enucleation","bipolar enucleation","2025-06-04",{"date":322,"type":30},"2025-06-13",{"date":324,"type":30},"2024-10-01",{"date":326,"type":21},"2025-11-01",{"name":328,"class":37},"Menoufia University",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":46,"enrollmentInfo":336,"targetDuration":4,"studyType":49,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":67},"100587021","real-time-trus-guidance-in-endoscopic-treatment-of-bph-100587021","NCT06922968","Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH","Standard Versus Transrectal Ultrasound (TRUS)-Guided Endoscopic Treatment of Benign Prostatic Hyperplasia: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 50-80 years\n* Diagnosed with benign prostatic hyperplasia (BPH) and scheduled for TURP or prostatic adenoma enucleation.\n* The patients have clear indication for endoscopic surgery (according to the guidelines).\n* Clinically fit patients for surgery.\n* Signed an informed consent.\n\nExclusion Criteria:\n\n* • Prostate cancer\n\n  * Previous urethral or prostate surgery\n  * Neurogenic bladder\n  * Urethral stricture",{"count":337,"type":21},114,[51],"The study aims to evaluate the role of TRUS in improving the efficacy and safety of endoscopic enucleation of prostate and TURP.",[25],"2025-04-09",{"date":343,"type":30},"2025-04-11",{"date":345,"type":21},"2025-04-01",{"date":347,"type":21},"2026-10-01",{"name":173,"class":37}]